Topiramate pharmacokinetics in children and adults with epilepsy: A case-matched comparison based on therapeutic drug monitoring data

Clinical Pharmacokinetics

Volumn 44, Issue 4, 2005, Pages 407-416

  Battino, Dina ^a   Croci, Danilo ^a   Rossini, Alessandro ^a   Messina, Sara ^b   Mamoli, Daniela ^a   Perucca, Emilia ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; INFANT; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANK SUM TEST;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INDUCTION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; INFANT; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 18644379814     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544040-00005     Document Type: Article

References (25)

1. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54 (5): 752-73
2. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001; 15 (6): 405-17
3. Kamin M. Topiramate: clinical efficacy and use in nonepileptic disorders. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. Philadelphia (PA): Lippincott, Williams & Wilkins, 2002: 753-9
4. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999; 52 (7): 1338-44
5. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52(7): 1330-7
6. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52 (9): 1882-7
7. Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999; 20 (5): 339-44
8. Glauser TA, Miles MV, Tang P, et al. Topiramate pharmacokinetics in infants. Epilepsia 1999; 40 (6): 788-91
9. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 2002; 24 (3): 366-74
10. Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003 Jul; 44 (7): 923-9
11. Berry DJ, Patsalos PN. Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. Ther Drug Monit 2000; 22 (4): 460-4
12. Contin M, Riva R, Albani F, et al. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant anuepileptic drugs. Ther Drug Monit 2002; 24 (3): 332-7
13. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitanl therapy. Epilepsia 1996; 37 (8): 774-80
14. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002; 43 (7): 691-6
15. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996; 37 Suppl. 2: S8-13
16. Bourgeois BF. Pharmacokinetics and pharmacodynamics of topiramate. J Child Neurol 2000; 15 Suppl. 1: S27-30
17. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31 (1): 29-46
18. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997; 38 (3): 324-33
19. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38 (3): 191-204
20. Twyman R, Ben-Menachem E, Veloso F. Plasma topiramate concentration versus therapeutic response during monotherapy. Epilepsia 1999; 40 Suppl.: 111-2
21. Reife R, Pledger G, Doose DR. Relationship of steady-state plasma topiramate concentration to clinical efficacy and tolerability [abstract]. Epilepsia 1995; 36 Suppl.: 152
22. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit 2004 Jun; 26 (3): 251-7
23. Dahlin MG, Ohman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol 2004 Oct; 31 (4): 248-53
24. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003 Dec; 25 (6): 700-8
25. Mikaeloff Y, Rey E, Soufflet C, et al. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 2004 Nov; 45 (11): 1448-52